Aspira Pathlab & Diagnostics Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Aspira Pathlab & Diagnostics has been growing earnings at an average annual rate of 21.4%, while the Healthcare industry saw earnings growing at 23.2% annually. Revenues have been growing at an average rate of 9.2% per year.
Key information
21.4%
Earnings growth rate
28.5%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 9.2% |
| Return on equity | -18.8% |
| Net Margin | -12.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Aspira Pathlab & Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 152 | -19 | 0 | 0 |
| 31 Mar 24 | 132 | -27 | 3 | 0 |
| 31 Dec 23 | 128 | -24 | 5 | 0 |
| 30 Jun 23 | 141 | -5 | 0 | 0 |
| 31 Mar 23 | 145 | -1 | 5 | 0 |
| 31 Dec 22 | 165 | 16 | 2 | 0 |
| 30 Sep 22 | 168 | 20 | 2 | 0 |
| 30 Jun 22 | 166 | 22 | 0 | 0 |
| 31 Mar 22 | 195 | 45 | 2 | 0 |
| 31 Dec 21 | 182 | 34 | 4 | 0 |
| 30 Jun 21 | 196 | 40 | 0 | 0 |
| 31 Mar 21 | 152 | 14 | 4 | 0 |
| 31 Dec 20 | 131 | -4 | 5 | 0 |
| 30 Jun 20 | 80 | -38 | 5 | 0 |
| 31 Mar 20 | 84 | -42 | 5 | 0 |
| 30 Sep 19 | 84 | -44 | 9 | 0 |
| 30 Jun 19 | 81 | -49 | 0 | 0 |
| 31 Mar 19 | 76 | -52 | 9 | 0 |
| 31 Mar 18 | 44 | -56 | 8 | 0 |
| 31 Mar 17 | 8 | -27 | 6 | 0 |
| 31 Mar 16 | 0 | 0 | 1 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
Quality Earnings: 540788 is currently unprofitable.
Growing Profit Margin: 540788 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 540788 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare 540788's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 540788 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (33.2%).
Return on Equity
High ROE: 540788 has a negative Return on Equity (-18.82%), as it is currently unprofitable.